Filing search / 1993-2019 / Teva Pharmaceutical Industries Limited / Page 35

SC TO-T/A

izt8wvpg

11 Feb 14

Third party tender offer statement (amended)

12:00am

6-K

5eimpln

6 Feb 14

Teva Reports Fourth Quarter and Full Year 2013 Results

12:00am

CORRESP

osuqk6yab ejh

4 Feb 14

Correspondence with SEC

12:00am

SC TO-T/A

wnjwsddrzniyr321pmd

4 Feb 14

Third party tender offer statement (amended)

12:00am

6-K

fhjgcw

29 Jan 14

Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mL

12:00am

6-K

w728dc

24 Jan 14

Live Filing

12:00am

SC TO-T

znnsb cupflj7qp

23 Jan 14

Third party tender offer statement

12:00am

6-K

q8e78 nwtwn4v

22 Jan 14

Phillip Frost, M.D. Chairman of the Board

12:00am

6-K

zo8zo6931gd6poyl y7

21 Jan 14

Teva Expands CNS Specialty Business with Acquisition of Nupathe

12:00am

SC TO-C

cngioh8dlmtork6n

21 Jan 14

Information about tender offer

12:00am

6-K

o9en08d xe1l

17 Jan 14

Current report (foreign)

12:00am

6-K

me6p3rwa7agfonmoz2

13 Jan 14

Live Filing

12:00am

6-K

5nl7fk2rv3e7tej350

9 Jan 14

Teva to Present at the32nd Annual J.P. Morgan Healthcare Conference

12:00am

6-K

xctbf3c emplxp

9 Jan 14

Teva Names Erez Vigodman as President and CEO

12:00am

6-K

1j2gifhfwesx xyqxtop

3 Jan 14

Live Filing

12:00am

6-K

t2c9gdl1hxm47zv46dso

24 Dec 13

Live Filing

12:00am

6-K

r83dzngx

19 Dec 13

Live Filing

12:00am

6-K

en5mqy3xa6vdq

17 Dec 13

Teva Settles Viagra® Patent Litigation with Pfizer

12:00am

6-K

j4q19nk

10 Dec 13

Teva Provides 2014 Non-GAAP Financial Outlook

12:00am